AbbVie touts Skyrizi ulcerative colitis data as it eyes another indication

Ab­b­Vie has tout­ed Skyrizi as a key pil­lar of its fu­ture be­yond Hu­mi­ra, and on Thurs­day, the com­pa­ny read out re­sults sug­gest­ing the IL-23 in­hibitor suc­ceed­ed as a main­te­nance ther­a­py for ul­cer­a­tive col­i­tis.

The phar­ma gi­ant re­port­ed that con­tin­ued treat­ment with Skyrizi (risankizum­ab) led to a “sig­nif­i­cant­ly high­er” rate of clin­i­cal re­mis­sion from ul­cer­a­tive col­i­tis com­pared to pa­tients who re­ceived on­ly in­duc­tion ther­a­py. The topline re­sults come just a few months af­ter Ab­b­Vie an­nounced that its Phase III in­duc­tion study met the pri­ma­ry and all sec­ondary end­points in adults with mod­er­ate­ly to se­vere­ly ac­tive ul­cer­a­tive col­i­tis.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN